bioAffinity Technologies, Inc.
No enriched coverage for $BIAF in the last 7 days.
No SEC Form 4 filings for $BIAF in the last 30 days.
See all $BIAF insider activity →bioAffinity Technologies (BIAF) will present CyPath Lung at CHEST 2026, highlighting its use in lung cancer risk assessment and new asthma/COPD inflammation test research. The company reported 92% sensitivity, 87% specificity, and 99% NPV in prior trials. The Medical and Scientific Advisory Board will discuss expansion and R&D programs.
bioAffinity Technologies will present data at CHEST 2026 on its investigational sputum test, which can detect lung inflammation protein biomarkers linked to asthma and COPD drug targets. The test, not yet FDA cleared, measures biomarkers like TSLP and IL-5, building on the company's CyPath Lung platform. According to the SEC filing, the test may help identify patients for biologic therapies with further validation.
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 Findings report on ability to measure cellular and soluble inflammatory
Recent BIAF coverage spans financial news, technology and corporate actions.
Positive trial results and upcoming conference exposure may boost investor sentiment for the micro‑cap biotech.
The first public disclosure of sputum biomarker data could lift sentiment if the results are viewed as promising for asthma and COPD therapeutics.
The announcement provides fresh research visibility for bioAffinity, but the test is still investigational and not commercialized.
Dilution from the new shares and warrants may weigh on the stock, while the cash proceeds provide modest working‑capital support.
Dilutive equity financing with warrants likely pressures near-term valuation, while funding supports CyPath Lung commercialization and working capital.
AlphAI scores every news story that mentions BIAF with an AI model for sentiment and relevance, and aggregates insider trades from bioAffinity Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
bioAffinity Technologies (BIAF) will present CyPath Lung at CHEST 2026, highlighting its use in lung cancer risk assessment and new asthma/COPD inflammation test research. The company reported 92% sensitivity, 87% specificity, and 99% NPV in prior trials. The Medical and Scientific Advisory Board will discuss expansion and R&D programs.
1 min readbioAffinity Technologies will present data at CHEST 2026 on its investigational sputum test, which can detect lung inflammation protein biomarkers linked to asthma and COPD drug targets. The test, not yet FDA cleared, measures biomarkers like TSLP and IL-5, building on the company's CyPath Lung platform. According to the SEC filing, the test may help identify patients for biologic therapies with further validation.
1 min readbioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 Findings report on ability to measure cellular and soluble inflammatory
2 min readbioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 News Release bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (October 8, 2026) – bioAffinity Technologies, Inc .
1 min readbioAffinity Technologies (NASDAQ: BIAF) raised $4M via a registered direct offering and private placement, selling shares and warrants at $6.122 each. Proceeds will support working capital and lung cancer test sales. WallachBeth Capital acted as placement agent. Closing expected October 9, 2026.
4 min readbioAffinity Technologies (BIAF) stock surged 31.48% to $8.09 on news of a Japanese patent allowance for its CyPath Lung test, which detects early-stage lung cancer. The patent is the first in Japan for the AI-driven test and the fifth in Asia. CEO Maria Zannes highlighted the patent's importance for market expansion and intellectual property protection.
2 min readbioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia
2 min readbioAffinity Technologies reported CyPath Lung sales grew over 100% through Q3 2026 compared to Q3 2025, driven by an 89% increase in ordering physicians and 48% higher repeat usage. Testing volume reached 1,620 tests, up from 775. The company also announced a new distribution deal with AvMEDICAL, according to an SEC filing.
1 min readbioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 Nearly 90% increase in number of physician offices using CyPath Lung Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by ne
2 min readbioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL Companies debut federal distribution collaboration to VA leadership, administrators a
2 min read
